The export-side mirror of this repo's import/PLI-coverage bulletin: maps the 12 fastest-growing/highest-value HSN export chapters to their actual top destination countries via TRADESTAT, ranks countries by cross-sector exposure, and checks which PLI sub-schemes — Auto, Bulk Drugs, Textiles/MMF — actually support these chapters.
Combined FY2025-26 export value across the 12 growth chapters where each country appears as a top-8 destination.
The USA is the top-8 destination in 11 of the 12 fastest-growing export chapters, ranking #1 or #2 in 9 of them — $63.9bn combined, more concentrated by both breadth and depth than China's grip on the import side (8 of 12 chapters, $102.4bn but spread across more evenly-ranked positions). UAE is the clear #2 destination (10 of 12 chapters, $26.9bn, #1/#2 in 6) — functioning as both a direct market and a regional re-export/refining hub. The next tier (Netherlands, China, Singapore, UK, Hong Kong, Germany) are each concentrated in 2-8 chapters at more modest shares.
Ranked by FY2025-26 export value, same order as the source chart.
PLI Auto & Auto Components (₹25,938 crore, FY2022-23 to FY2026-27, approved September 2021) targets Advanced Automotive Technology products — battery-electric and hydrogen fuel-cell vehicles specifically — and directly supports HS87 (vehicles, +43.5% growth, USA/Mexico/South Africa/Saudi Arabia as top destinations). Budget 2026-27 nearly tripled its allocation to ₹5,939.87 crore from the FY2025-26 revised estimate of ₹2,091.26 crore. The complementary ACC Battery Storage PLI (₹18,100 crore, targeting 50 GWh capacity, 40 GWh already awarded) feeds the same EV value chain.
PLI Bulk Drugs (₹6,940 crore, FY2022-23 to FY2028-29) is the clearest cross-link between this bulletin and the companion import-side analysis: 48 projects selected, 34 commissioned across 25-26 APIs/KSMs/intermediates, ₹4,709 crore invested against a ₹3,938.5 crore commitment, generating ₹1,962 crore in sales (₹479 crore of it exports) and avoiding an estimated ₹1,483 crore in imports — explicitly aimed at cutting India's roughly 70% dependence on Chinese bulk-drug imports. It doesn't directly target HS30 (pharmaceutical formulations, +69.9% growth, 34.6% to the USA) but supports it indirectly by reducing the HS29 (organic chemicals/API) import dependency that formulation exports rely on.
Iron & steel (HS72) and iron/steel articles (HS73) carry the same Specialty Steel PLI coverage (₹44,106 crore in rounds 1.0/1.1, plus ₹11,887 crore in round 1.2, MoUs signed February 2026) documented on the import side of this repo's analysis — one of the few schemes with genuinely matched coverage on both the import-substitution and export-growth sides of the same chapter.